Fuertes Abardia C, Ballesta Juan P, Cruz Esteve I, Galindo Ortego G, Marsal Mora JR, Gomez-Arbones X. Potentially inappropriate prescribing: usefulness of STOPP/START criteria version 2 in Catalonian elderly population. Semergen. 2022 Apr;48(3):163-73. doi: 10.1016/j.semerg.2021.09.005
Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Pifarre J, Barbe F. Comorbidity in mental health in patients diagnosed with chronic obstructive pulmonary disease. Semergen. 2020 Jan;46(1):53-9. doi: 10.1016/j.semerg.2019.08.002
Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France. Adv Hematol. 2019 Jan 29;2019(4625787). doi: 10.1155/2019/4625787
Davis KL, Cote I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015 Oct;2015(2015):848473. doi: 10.1155/2015/848473
Kovac AL, Pearman MH, Khalil SN, Scuderi PE, Joslyn AF, Prillaman BA, Cox F. Ondansetron prevents postoperative emesis in male outpatients.S3A-379 study group. J Clin Anesth. 1996 Dec;8(8):644-51. doi: 10.1016/s0952-8180(96)00173-0